Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
25 July 2014Website:
http://www.ocutx.comNext earnings report:
11 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:29:31 GMTDividend
Analysts recommendations
Institutional Ownership
OCUL Latest News
BEDFORD, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced upcoming presentations at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV.
BEDFORD, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it plans to host a conference call and webcast on Thursday, November 14, 2024, at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2024.
Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BEDFORD, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced participation in multiple panels and presentations across three ophthalmology meetings in Chicago, Illinois during October 2024.
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in September 2024.
BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September:
The consensus price target hints at an 85.4% upside potential for Ocular Therapeutix (OCUL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Biren Amin - Piper Sandler Tara Bancroft - TD Cowen Colleen Kusy - Baird Kelly Shi - Jefferies Sean McCutcheon - Raymond James Yi Chen - H.C. Wainwright & Co. Operator Good morning, and welcome to the Ocular Therapeutix second-quarter 2024 earnings conference call.
Ocular Therapeutix is a biopharmaceutical company with a successful commercial product, Dextenza, generating $57.9 million in revenue in 2023. The company's main value driver is Axpaxli, an axitinib intravitreal implant in phase 3 trials for wet age-related macular degeneration (wet AMD). The company has a strong financial position with $482.9 million in cash and a 3.5-year cash runway, minimizing dilution risk.
The 2024 OIS Retina and ARVO conferences are taking place in Seattle, Washington.
- 1(current)
- 2
What type of business is Ocular Therapeutix?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
What sector is Ocular Therapeutix in?
Ocular Therapeutix is in the Healthcare sector
What industry is Ocular Therapeutix in?
Ocular Therapeutix is in the Biotechnology industry
What country is Ocular Therapeutix from?
Ocular Therapeutix is headquartered in United States
When did Ocular Therapeutix go public?
Ocular Therapeutix initial public offering (IPO) was on 25 July 2014
What is Ocular Therapeutix website?
https://www.ocutx.com
Is Ocular Therapeutix in the S&P 500?
No, Ocular Therapeutix is not included in the S&P 500 index
Is Ocular Therapeutix in the NASDAQ 100?
No, Ocular Therapeutix is not included in the NASDAQ 100 index
Is Ocular Therapeutix in the Dow Jones?
No, Ocular Therapeutix is not included in the Dow Jones index
When was Ocular Therapeutix the previous earnings report?
No data
When does Ocular Therapeutix earnings report?
The next expected earnings date for Ocular Therapeutix is 11 March 2025